# Non-Small Cell Lung Cancer FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/non-small-cell-lung-cancer

> 55 upcoming FDA catalysts in Non-Small Cell Lung Cancer: Imfinzi® (durvalumab, AZN) on Jan to Apr 2027 (topline data readout); Imfinzi® (durvalumab, AZN) on January 2027 (primary completion); Opdivo® (nivolumab, BMY) on Feb to May 2027 (topline data readout); Opdivo® (nivolumab, BMY) on February 2027 (primary completion); and 51 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for Non-Small Cell Lung Cancer?

55 upcoming FDA catalysts in Non-Small Cell Lung Cancer: Imfinzi® (durvalumab, AZN) on Jan to Apr 2027 (topline data readout); Imfinzi® (durvalumab, AZN) on January 2027 (primary completion); Opdivo® (nivolumab, BMY) on Feb to May 2027 (topline data readout); Opdivo® (nivolumab, BMY) on February 2027 (primary completion); and 51 more. SEC Form 10-Q: "AIM anticipates topline results in the first quarter of 2027, followed by the analysis of overall survival in the third quarter of 2027." [Calendar and source filings](https://sec-api.dev/indications/non-small-cell-lung-cancer)

Source: SEC Form 10-Q, accession 0001493152-26-051439, https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm (retrieved 2026-11-13). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/non-small-cell-lung-cancer#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 2025 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | delayed | "NCT03944772 (Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-05-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03944772)) |
| May 28, 2025 | [LUMYKRAS™ (sotorasib) primary completion](https://sec-api.dev/pdufa/sotorasib) | AMGN | Non-small Cell Lung Cancer | withdrawn | "NCT04933695 (A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-05-28 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-07-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04933695)) |
| June 11, 2025 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | completed | "NCT04919811 (Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-06-11 (ACTUAL); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04919811)) |
| July 9, 2025 | [Cab-axl-adc primary completion](https://sec-api.dev/pdufa/cab-axl-adc) | BCAB | Non-Small-Cell Lung Cancer | completed | "NCT04681131 (CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-09 (ACTUAL); Lead Sponsor BioAtla, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04681131)) |
| October 13, 2025 | [Nai + pembrolizumab primary completion](https://sec-api.dev/pdufa/nai-pembrolizumab) | IBRX | Non Small Cell Lung Cancer | withdrawn | "NCT03520686 (Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor ImmunityBio, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03520686)) |
| January 12, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | completed | "NCT05925530 (Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-01-12 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05925530)) |
| May 4, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | completed | "NCT06606847 (A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-05-04 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06606847)) |
| July 2026 | [Telisotuzumab vedotin primary completion](https://sec-api.dev/pdufa/telisotuzumab-vedotin) | ABBV | Non-small Cell Lung Cancer | delayed | "NCT03539536 (Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-07 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03539536)) |
| July 10, 2026 | [Datopotamab deruxtecan primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-small Cell Lung Cancer | completed | "NCT06564844 (A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-07-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564844)) |
| August 10, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | completed | "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05211895)) |
| Aug to Nov 2026 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05211895 (A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-10 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05211895)) |
| September 3, 2026 | [JDQ443 primary completion](https://sec-api.dev/pdufa/jdq443) | NVS | Non-Small Cell Lung Cancer | withdrawn | "NCT05132075 (Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2026-09-03 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05132075)) |
| Jan to Apr 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "AIM anticipates topline results in the first quarter of 2027, followed by the analysis of overall survival in the third quarter of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/946644/000149315226051439/form10-q.htm)) |
| January 2027 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05221840 (A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-08 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05221840)) |
| Feb to May 2027 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946797)) |
| February 2027 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT06946797 (A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-05 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946797)) |
| March 2027 | [Sacituzumab govitecan-hziy (sg) primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05186974 (Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05186974)) |
| Mar to Jun 2027 | [Sacituzumab govitecan-hziy (sg) topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05186974 (Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05186974)) |
| June 2027 | [Iph5201 + durvalumab + standard chemotherapy primary completion](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) | IPHA | Non Small Cell Lung Cancer | scheduled | "NCT05742607 (IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Innate Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742607)) |
| Jun to Sep 2027 | [Iph5201 + durvalumab + standard chemotherapy topline data readout](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) | IPHA | Non Small Cell Lung Cancer | scheduled | "NCT05742607 (IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Innate Pharma." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05742607)) |
| June 2027 | [VS-7375 primary completion](https://sec-api.dev/pdufa/vs-7375) | VSTM | Non-Small Cell Lung Cancer | scheduled | "NCT07659782 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659782)) |
| Jun to Sep 2027 | [VS-7375 topline data readout](https://sec-api.dev/pdufa/vs-7375) | VSTM | Non-Small Cell Lung Cancer | scheduled | "NCT07659782 (A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-06 (ESTIMATED); Lead Sponsor Verastem, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07659782)) |
| 2H 2027 | [Sacituzumab tirumotecan interim data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | CBIO | non-small cell lung cancer | scheduled | "We also initiated a global Phase 1/2 trial of CR-002 (the "APOLLO trial") in the fourth quarter of 2026, with initial data expected in the second half of 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1253689/000162828026073389/cbio-20260930.htm)) |
| Jul to Oct 2027 | [Volrustomig topline data readout](https://sec-api.dev/pdufa/volrustomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06448754 (Volrustomig Priming Regimens Exploratory Phase II Platform Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06448754)) |
| July 2027 | [Volrustomig primary completion](https://sec-api.dev/pdufa/volrustomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06448754 (Volrustomig Priming Regimens Exploratory Phase II Platform Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-07-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06448754)) |
| Aug to Nov 2027 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05120349)) |
| August 2027 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT05120349 (A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-02 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05120349)) |
| Jan to Apr 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345729)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345729)) |
| Mar to Jun 2028 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350097)) |
| March 2028 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06350097 (Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-03-21 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06350097)) |
| April 2028 | [Ivonescimab primary completion](https://sec-api.dev/pdufa/ivonescimab) | SMMT | Non-Small Cell Lung Cancer | scheduled | "NCT06767514 (Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Summit Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06767514)) |
| Apr to Jul 2028 | [Ivonescimab topline data readout](https://sec-api.dev/pdufa/ivonescimab) | SMMT | Non-Small Cell Lung Cancer | scheduled | "NCT06767514 (Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-04 (ESTIMATED); Lead Sponsor Summit Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06767514)) |
| May to Aug 2028 | [ORPATHYS® (savolitinib) topline data readout](https://sec-api.dev/pdufa/savolitinib) | HCM | Non-small Cell Lung Cancer | scheduled | "NCT05009836 (Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05009836)) |
| May 2028 | [ORPATHYS® (savolitinib) primary completion](https://sec-api.dev/pdufa/savolitinib) | HCM | Non-small Cell Lung Cancer | scheduled | "NCT05009836 (Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-05-30 (ESTIMATED); Lead Sponsor Hutchmed." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05009836)) |
| June 2028 | [YuTuo (zimberelimab) primary completion](https://sec-api.dev/pdufa/zimberelimab) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502237)) |
| Jun to Sep 2028 | [YuTuo (zimberelimab) topline data readout](https://sec-api.dev/pdufa/zimberelimab) | GILD | Non-small Cell Lung Cancer | scheduled | "NCT05502237 (Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05502237)) |
| October 2028 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06841055 (Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841055)) |
| Oct 2028 to Jan 2029 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06841055 (Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-10 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841055)) |
| Dec 2028 to Mar 2029 | [Ivonescimab topline data readout](https://sec-api.dev/pdufa/ivonescimab) | SMMT | Non-Small Cell Lung Cancer | scheduled | "NCT05899608 (Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Summit Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05899608)) |
| Dec 2028 to Mar 2029 | [Iza-bren topline data readout](https://sec-api.dev/pdufa/iza-bren) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT07100080 (Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100080)) |
| December 2028 | [Iza-bren primary completion](https://sec-api.dev/pdufa/iza-bren) | BMY | Non-Small Cell Lung Cancer | scheduled | "NCT07100080 (Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2028-12-15 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07100080)) |
| December 2028 | [Ivonescimab primary completion](https://sec-api.dev/pdufa/ivonescimab) | SMMT | Non-Small Cell Lung Cancer | scheduled | "NCT05899608 (Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-31 (ESTIMATED); Lead Sponsor Summit Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05899608)) |
| January 2029 | [IBTROZI (taletrectinib) primary completion](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | scheduled | "NCT06564324 (A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564324)) |
| Jan to Apr 2029 | [IBTROZI (taletrectinib) topline data readout](https://sec-api.dev/pdufa/taletrectinib) | NUVB | Non Small Cell Lung Cancer | scheduled | "NCT06564324 (A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor Nuvation Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06564324)) |
| January 2029 | [Pumitamig primary completion](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06712316 (Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712316)) |
| Jan to Apr 2029 | [Pumitamig topline data readout](https://sec-api.dev/pdufa/pumitamig) | BNTX | Non-small Cell Lung Cancer | scheduled | "NCT06712316 (Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01 (ESTIMATED); Lead Sponsor BioNTech SE." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06712316)) |
| Apr to Jul 2029 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT07098338 (A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07098338)) |
| April 2029 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT07098338 (A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-06 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07098338)) |
| Jun to Sep 2029 | [Tagrisso® (osimertinib) topline data readout](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05546866 (Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05546866)) |
| June 2029 | [Tagrisso® (osimertinib) primary completion](https://sec-api.dev/pdufa/osimertinib) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05546866 (Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-06-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05546866)) |
| Dec 2029 to Mar 2030 | [Datopotamab deruxtecan topline data readout](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT06357533 (Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06357533)) |
| Dec 2029 to Mar 2030 | [Calderasib topline data readout](https://sec-api.dev/pdufa/calderasib) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT07190248 (A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190248)) |
| December 2029 | [ABBV-1480 primary completion](https://sec-api.dev/pdufa/abbv-1480) | ABBV | Non-Small Cell Lung Cancer | scheduled | "NCT07756645 (A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07756645)) |
| Dec 2029 to Mar 2030 | [ABBV-1480 topline data readout](https://sec-api.dev/pdufa/abbv-1480) | ABBV | Non-Small Cell Lung Cancer | scheduled | "NCT07756645 (A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07756645)) |
| December 2029 | [Calderasib primary completion](https://sec-api.dev/pdufa/calderasib) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT07190248 (A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190248)) |
| December 2029 | [Datopotamab deruxtecan primary completion](https://sec-api.dev/pdufa/datopotamab-deruxtecan) | AZN | Non-Small Cell Lung Cancer | scheduled | "NCT06357533 (Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06357533)) |
| Jan to Apr 2030 | [Fianlimab topline data readout](https://sec-api.dev/pdufa/fianlimab) | REGN | Non-small Cell Lung Cancer | scheduled | "NCT05800015 (A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-16 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05800015)) |
| January 2030 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Non-small Cell Lung Cancer | scheduled | "NCT05800015 (A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2030-01-16 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05800015)) |
| May to Aug 2030 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05061550 (Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05061550)) |
| May 2030 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT05061550 (Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2030-05-28 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05061550)) |
| Jun to Sep 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06077760 (A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06077760)) |
| June 2030 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06077760 (A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06077760)) |
| Jul to Oct 2030 | [Opdivo® (nivolumab) topline data readout](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-small Cell Lung Cancer | scheduled | "NCT06561386 (A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-30 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06561386)) |
| July 2030 | [Rilvegostomig primary completion](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06692738 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06692738)) |
| Jul to Oct 2030 | [Rilvegostomig topline data readout](https://sec-api.dev/pdufa/rilvegostomig) | AZN | Non-small Cell Lung Cancer | scheduled | "NCT06692738 (A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-01 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06692738)) |
| July 2030 | [Opdivo® (nivolumab) primary completion](https://sec-api.dev/pdufa/nivolumab) | BMY | Non-small Cell Lung Cancer | scheduled | "NCT06561386 (A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-07-30 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06561386)) |

## Drugs

- [Tagrisso® (osimertinib)](https://sec-api.dev/pdufa/osimertinib) (AZN)
- [LUMYKRAS™ (sotorasib)](https://sec-api.dev/pdufa/sotorasib) (AMGN)
- [IBTROZI (taletrectinib)](https://sec-api.dev/pdufa/taletrectinib) (NUVB)
- [Cab-axl-adc](https://sec-api.dev/pdufa/cab-axl-adc) (BCAB)
- [Nai + pembrolizumab](https://sec-api.dev/pdufa/nai-pembrolizumab) (IBRX)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)
- [Telisotuzumab vedotin](https://sec-api.dev/pdufa/telisotuzumab-vedotin) (ABBV)
- [Datopotamab deruxtecan](https://sec-api.dev/pdufa/datopotamab-deruxtecan) (AZN)
- [JDQ443](https://sec-api.dev/pdufa/jdq443) (NVS)
- [Opdivo® (nivolumab)](https://sec-api.dev/pdufa/nivolumab) (BMY)
- [Sacituzumab govitecan-hziy (sg)](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy-sg) (GILD)
- [Iph5201 + durvalumab + standard chemotherapy](https://sec-api.dev/pdufa/iph5201-durvalumab-standard-chemotherapy) (IPHA)
- [VS-7375](https://sec-api.dev/pdufa/vs-7375) (VSTM)
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) (MRK)
- [Volrustomig](https://sec-api.dev/pdufa/volrustomig) (AZN)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Ivonescimab](https://sec-api.dev/pdufa/ivonescimab) (SMMT)
- [ORPATHYS® (savolitinib)](https://sec-api.dev/pdufa/savolitinib) (HCM)
- [YuTuo (zimberelimab)](https://sec-api.dev/pdufa/zimberelimab) (GILD)
- [Pumitamig](https://sec-api.dev/pdufa/pumitamig) (BMY)
- [Iza-bren](https://sec-api.dev/pdufa/iza-bren) (BMY)
- [Rilvegostomig](https://sec-api.dev/pdufa/rilvegostomig) (AZN)
- [Calderasib](https://sec-api.dev/pdufa/calderasib) (MRK)
- [ABBV-1480](https://sec-api.dev/pdufa/abbv-1480) (ABBV)
- [Fianlimab](https://sec-api.dev/pdufa/fianlimab) (REGN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/non-small-cell-lung-cancer.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Non-Small Cell Lung Cancer FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/non-small-cell-lung-cancer

```bibtex
@misc{secapidev_indications_non_small_cell_lung_cancer_20261116,
  title        = {Non-Small Cell Lung Cancer FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/non-small-cell-lung-cancer}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_non_small_cell_lung_cancer_20261116","title":"Non-Small Cell Lung Cancer FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/non-small-cell-lung-cancer","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
